NCT06050941View on ClinicalTrials.gov

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

April 2, 2026

Study Completion Date

April 2, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

idarubicin

Idarubicin 6mg/m2 d5-7

DRUG

Cytarabine

Cytarabine 60mg/m2 d5-9

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER

NCT06050941 - Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | Biotech Hunter | Biotech Hunter